Engineered lentivector targeting of dendritic cells for in vivo immunization

Nature Biotechnology

Volumn 26, Issue 3, 2008, Pages 326-334

  Yang, Lili ^a   Yang, Haiguang ^b   Rideout, Kendra ^b   Cho, Taehoon ^b   Joo, Kye Il ^b   Ziegler, Leslie ^b   Elliot, Abigail ^a   Walls, Anthony ^a   Yu, Dongzi ^a   Baltimore, David ^a   Wang, Pin ^b  

^a CALIFORNIA INSTITUTE OF TECHNOLOGY   (United States)

^b HED 216 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODIES; ANTIGENS; CELL CULTURE; GLYCOPROTEINS; IMMUNIZATION; TUMORS;

DENDRITIC CELL MATURATION; DENDRITIC CELLS; LENTIVIRAL VECTORS; OVALBUMINS;

VIRUSES;

CD209 ANTIGEN; CELL SURFACE PROTEIN; GLYCOPROTEIN; LENTIVIRUS VECTOR; OVALBUMIN;

ANIMAL CELL; ANTIBODY RESPONSE; ARTICLE; CD8+ T LYMPHOCYTE; CELL MATURATION; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; HUMAN; HUMAN CELL; IMMUNITY; IMMUNIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ENGINEERING; SINDBIS VIRUS; TRANSGENE; VIRUS ENVELOPE;

ANIMALS; B-LYMPHOCYTES; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL ADHESION MOLECULES; CELL LINE; DENDRITIC CELLS; FEMALE; GENE EXPRESSION; GENETIC VECTORS; HUMANS; LECTINS, C-TYPE; LENTIVIRUS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASMS, EXPERIMENTAL; OVALBUMIN; RECEPTORS, CELL SURFACE; SENSITIVITY AND SPECIFICITY; SINDBIS VIRUS; TRANSDUCTION, GENETIC;

MUS; SINDBIS VIRUS;

EID: 40449116336     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt1390     Document Type: Article

References (48)

1. Rosenberg, S.A., Yang, J.C. & Restifo, N.P. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10, 909-915 (2004).
2. Banchereau, J. & Steinman, R.M. Dendritic cells and the control of immunity. Nature 392, 245-252 (1998).
3. Banchereau, J. & Palucka, A.K. Dendritic cells as therapeutic vaccines against cancer. Nat. Rev. Immunol. 5, 296-306 (2005).
4. Figdor, C.G., de Vries, I.J., Lesterhuis, W.J. & Melief, C.J. Dendritic cell immunotherapy: mapping the way. Nat. Med. 10, 475-480 (2004).
5. Schuler, G., Schuler-Thurner, B. & Steinman, R.M. The use of dendritic cells in cancer immunotherapy. Curr. Opin. Immunol. 15, 138-147 (2003).
6. Ribas, A., Butterfield, L.H., Glaspy, J.A. & Economou, J.S. Cancer immunotherapy using gene-modified dendritic cells. Curr. Gene Ther. 2, 57-78 (2002).
7. Kirk, C.J. & Mule, J.J. Gene-modified dendritic cells for use in tumor vaccines. Hum. Gene Ther. 11, 797-806 (2000).
8. Song, W., Tong, Y., Carpenter, H., Kong, H.L. & Crystal, R.G. Persistent, antigen-specific, therapeutic antitumor immunity by dendritic cells genetically modified with an adenoviral vector to express a model tumor antigen. Gene Ther. 7, 2080-2086 (2000).
9. Gong, J. et al. Induction of antigen-specific antitumor immunity with adenovirus-transduced dendritic cells. Gene Ther. 4, 1023-1028 (1997).
10. Kaplan, J.M. et al. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens. J. Immunol. 163, 699-707 (1999).
11. Meyer zum Buschenfelde, C., Nicklisch, N., Rose-John, S., Peschel, C. & Bernhard, H. Generation of tumor-reactive CTL against the tumor-associated antigen HER2 using retrovirally transduced dendritic cells derived from CD34+ hemopoietic progenitor cells. J. Immunol. 165, 4133-4140 (2000).
12. Temme, A. et al. Efficient transduction and long-term retroviral expression of the melanoma-associated tumor antigen tyrosinase in CD34(+) cord blood-derived dendritic cells. Gene Ther. 9, 1551-1560 (2002).
13. Mangeot, P.E. et al. Development of minimal lentivirus vectors derived from simian immunodeficiency virus (SIVmac251) and their use for gene transfer into human dendritic cells. J. Virol. 74, 8307-8315 (2000).
14. Schroers, R. & Chen, S.Y. Lentiviral transduction of human dendritic cells. Methods Mol. Biol. 246, 451-459 (2004).
15. Esslinger, C., Romero, P. & MacDonald, H.R. Efficient transduction of dendritic cells and induction of a T-cell response by third-generation lentivectors. Hum. Gene Ther. 13, 1091-1100 (2002).
16. Barouch, D.H. & Nabel, G.J. Adenovirus vector-based vaccines for human immunodeficiency virus type 1. Hum. Gene Ther. 16, 149-156 (2005).
17. Shiver, J.W. & Emini, E.A. Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. Annu. Rev. Med. 55, 355-372 (2004).
18. Tatsis, N. & Ertl, H.C. Adenoviruses as vaccine vectors. Mol. Ther. 10, 616-629 (2004).
19. Breckpot, K., Aerts, J.L. & Thielemans, K. Lentiviral vectors for cancer immunotherapy: transforming infectious particles into therapeutics. Gene Ther. 14, 847-862 (2007).
20. Esslinger, C. et al. In vivo administration of a lentiviral vaccine targets DCs and induces efficient CD8(+) T cell responses. J. Clin. Invest. 111, 1673-1681 (2003).
21. Kim, J.H. et al. Induction of therapeutic antitumor immunity by in vivo administration of a lentiviral vaccine. Hum. Gene Ther. 16, 1255-1266 (2005).
22. Dullaers, M. et al. Induction of effective therapeutic antitumor immunity by direct in vivo administration of lentiviral vectors. Gene Ther. 13, 630-640 (2006).
23. Cheng, C. et al. Mechanism of ad5 vaccine immunity and toxicity: fiber shaft targeting of dendritic cells. PLoS Pathog. 3, e25 (2007).
24. de Gruijl, T.D. et al. Prolonged maturation and enhanced transduction of dendritic cells migrated from human skin explants after in situ delivery of CD40-targeted adenoviral vectors. J. Immunol. 169, 5322-5331 (2002).
25. Belousova, N. et al. Genetically targeted adenovirus vector directed to CD40-expressing cells. J. Virol. 77, 11367-11377 (2003).
26. Bonifaz, L. et al. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J. Exp. Med. 196, 1627-1638 (2002).
27. Bonifaz, L.C. et al. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J. Exp. Med. 199, 815-824 (2004).
28. Trumpfheller, C. et al. Intensified and protective CD4+ T cell immunity in mice with anti-dendritic cell HIV gag fusion antibody vaccine. J. Exp. Med. 203, 607-617 (2006).
29. Tacken, P.J., de Vries, I.J., Torensma, R. & Figdor, C.G. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat. Rev. Immunol. 7, 790-802 (2007).
30. Dakappagari, N. et al. Internalizing antibodies to the C-type lectins, L-SIGN and DC-SIGN, inhibit viral glycoprotein binding and deliver antigen to human dendritic cells for the induction of T cell responses. J. Immunol. 176, 426-440 (2006).
31. Geijtenbeek, T.B. et al. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 100, 587-597 (2000).
32. Geijtenbeek, T.B. et al. Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses. Cell 100, 575-585 (2000).
33. Geijtenbeek, T.B., van Vliet, S.J., Engering, A., t Hart, B.A. & van Kooyk, Y. Self- and nonself-recognition by C-type lectins on dendritic cells. Annu. Rev. Immunol. 22, 33-54 (2004).
34. Klimstra, W.B., Nangle, E.M., Smith, M.S., Yurochko, A.D. & Ryman, K.D. DC-SIGN and L-SIGN can act as attachment receptors for alphaviruses and distinguish between mosquito cell- and mammalian cell-derived viruses. J. Virol. 77, 12022-12032 (2003).
35. Strauss, J.H., Wang, K.S., Schmaljohn, A.L., Kuhn, R.J. & Strauss, E.G. Host-cell receptors for Sindbis virus. Arch. Virol. 9, 473-484 (1994).
36. Byrnes, A.P. & Griffin, D.E. Binding of Sindbis virus to cell surface heparan sulfate. J. Virol. 72, 7349-7356 (1998).
37. Morizono, K. et al. Lentiviral vector retargeting to P-glycoprotein on metastatic melanoma through intravenous injection. Nat. Med. 11, 346-352 (2005).
38. Yang, L., Bailey, L., Baltimore, D. & Wang, P. Targeting lentiviral vectors to specific cell types in vivo. Proc. Natl. Acad. Sci. USA 103, 11479-11484 (2006).
39. Lois, C., Hong, E.J., Pease, S., Brown, E.J. & Baltimore, D. Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors. Science 295, 868-872 (2002).
40. Butler, S.L., Hansen, M.S. & Bushman, F.D. A quantitative assay for HIV DNA integration in vivo. Nat. Med. 7, 631-634 (2001).
41. Steinman, R.M., Hawiger, D. & Nussenzweig, M.C. Tolerogenic dendritic cells. Annu. Rev. Immunol. 21, 685-711 (2003).
42. Yang, L. & Baltimore, D. Long-term in vivo provision of antigen-specific T cell immunity by programming hematopoietic stem cells. Proc. Natl. Acad. Sci. USA 102, 4518-4523 (2005).
43. Zhou, T., Chen, Y., Hao, L. & Zhang, Y. DC-SIGN and immunoregulation. Cell Mol. Immunol. 3, 279-283 (2006).
44. Matsuno, K., Ezaki, T., Kudo, S. & Uehara, Y. A life stage of particle-laden rat dendritic cells in vivo: their terminal division, active phagocytosis, and translocation from the liver to the draining lymph. J. Exp. Med. 183, 1865-1878 (1996).
45. Shen, L., Evel-Kabler, K., Strube, R. & Chen, S.Y. Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specific anti-tumor immunity. Nat. Biotechnol. 22, 1546-1553 (2004).
46. Park, D., Lapteva, N., Seethammagari, M., Slawin, K.M. & Spencer, D.M. An essential role for Akt1 in dendritic cell function and tumor immunotherapy. Nat. Biotechnol. 24, 1581-1590 (2006).
47. Takahara, K. et al. Functional comparison of the mouse DC-SIGN, SIGNR1, SIGNR3 and Langerin, C-type lectins. Int. Immunol. 16, 819-829 (2004).
48. Powlesland, A.S. et al. Widely divergent biochemical properties of the complete set of mouse DC-SIGN-related proteins. J. Biol. Chem. 281, 20440-20449 (2006).